Compare ELMD & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | MIST |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 176.3M |
| IPO Year | 2010 | 2019 |
| Metric | ELMD | MIST |
|---|---|---|
| Price | $24.27 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.00 | $8.50 |
| AVG Volume (30 Days) | 40.1K | ★ 2.9M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | $2,915.14 |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $43.59 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $0.77 |
| 52 Week High | $30.73 | $3.06 |
| Indicator | ELMD | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 67.48 |
| Support Level | $23.29 | $1.89 |
| Resistance Level | $25.31 | $2.28 |
| Average True Range (ATR) | 0.85 | 0.16 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 60.45 | 86.32 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).